Announced
Financials
Tags
Sweden
drug development
Pharmaceuticals
Acquisition
Cross Border
Private
Majority
Pending
Single Bidder
Friendly
Synopsis
SSI Strategy, a life sciences consultancy, agreed to acquire NDA Group, a regulatory affairs and drug development consultancy company. Financial terms were not disclosed. “NDA Group is regarded as the premier regulatory consultancy for Life Sciences companies across the US and Europe, and we’re delighted to build upon our longstanding partnership with this combination,” Doug Locke, SSI Strategy Chief Executive Officer.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.